Fig. 6: Genomic alterations in patients with short and long TTF to CDK4/6i retrial in Cohort 3. | npj Breast Cancer

Fig. 6: Genomic alterations in patients with short and long TTF to CDK4/6i retrial in Cohort 3.

From: Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Fig. 6

Somatic tumor mutation profiles of patients in Cohort 3 that had good response (>9 months TTF) and poor response (<4 months TTF) for CDK4/6i retrial. Each column represents an individual patient, organized first by BOR by PRISSMM criteria then by timing of mutational profile sample (Before first CDK4/6i, In-Between initial exposure and retrial, or After CDK4/6i retrial). RB1 and FAT1 loss of function mutations as well as CDK4 amplifcations were seen exclusively in patients with TTF < 4months. Two patients in the TTF > 9 months had FAT1 mutations that were variants of unknown significance. Other classical ER + MBC resistance mutations, such as those in TP53, PIK3CA, and ESR1 were fairly evenly distributed between the two subgroups.

Back to article page